Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients

Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients

Abstract Background Compared to the general population, cancer patients are at higher risk of morbidity and mortality following SARS‐CoV‐2 infection. The immune response to a two‐dose regimen of mRNA vaccines in cancer patients is generally lower than in immunocompetent individuals. Booster doses ma...

Full description

Bibliographic Details
Main Authors: Anna Giuliano, Barbara Kuter, Shari Pilon‐Thomas, Junmin Whiting, Qianxing Mo, Brett Leav, Bradley Sirak, Christopher Cubitt, Christopher Dukes, Kimberly Isaacs‐Soriano, Kayoko Kennedy, Somedeb Ball, Ning Dong, Akriti Jain, Patrick Hwu, Jeffrey Lancet
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:Cancer Communications
Subjects:
Cancer
Coronavirus disease 2019
Immunogenicity
Observational study
Vaccination
Online Access:https://doi.org/10.1002/cac2.12453

Internet

https://doi.org/10.1002/cac2.12453

Similar Items